lithera.com
FOR IMMEDIATE RELEASE Lithera to Present at Three Upcoming Conferences SAN DIEGO, Calif. – October 5, 2010 – Lithera, Inc. today announced that it will present key clinical data and progress updates on the development of LIPO-102, its novel injectable combination of salmeterol xinafoate (SX) and fluticasone propionate (FP) for selective, non-ablative fat reduction. Lithera wil